385 related articles for article (PubMed ID: 12867223)
1. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Weiss R; Harder M; Rowe J
Clin Ther; 2003 May; 25(5):1490-7. PubMed ID: 12867223
[TBL] [Abstract][Full Text] [Related]
2. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
[TBL] [Abstract][Full Text] [Related]
3. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
Stacy TA; Egger A
J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
[TBL] [Abstract][Full Text] [Related]
4. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.
Desmeules S; Arcand-Bossé JF; Bergeron J; Douville P; Agharazii M
Am J Kidney Dis; 2005 Jun; 45(6):1067-72. PubMed ID: 15957136
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
8. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
10. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
[TBL] [Abstract][Full Text] [Related]
11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
13. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
15. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
18. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
20. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]